Treat FTD Fund
Expire le 7 octobre 2024
AFTD, in partnership with the Alzheimer’s Drug Discovery Foundation (ADDF) launched the Treat FTD Fund in 2016 to address the unique challenges of developing effective treatments for FTD disorders. Early-stage clinical trials supported through the Treat FTD Fund will build on our growing understanding of the biological mechanisms underlying FTD and will complement other AFTD grant programs such as the FTD Biomarkers Initiative and the Accelerating Drug Discovery for FTD program by leveraging progress in biomarker development and preclinical research.
Program Goals: 2024 – 2025 Funding Cycle
The Treat FTD Fund seeks to support clinical trials incorporating:
- biological mechanisms that have a sound scientific rationale for FTD
- biomarkers that would permit evaluation of target engagement, downstream pharmacologic effect, and biological effect
- trial designs aligned with constraints associated with a rare disease population
- clinical outcome measures that could provide a deeper understanding of the drug mechanism and disease progression
- therapeutics applicable to sporadic or genetic forms of FTD. Trials of treatments applicable in sporadic FTD are especially encouraged.
More details
Website: https://www.theaftd.org/for-researchers/funding-opportunities/treatftd-initiative/